Industry Investment Rating - The industry investment rating is maintained at "Outperform the Market" [1] Core Insights - The report highlights that the domestic PFA brands are expected to enter a commercialization fast track in 2025, driven by their non-thermal ablation characteristics, shorter operation times, lower complication risks, and better long-term efficacy [5][6] - The pharmaceutical and biotechnology sector experienced a decline of 4.35% this week, underperforming the CSI 300 index by 3.9 percentage points, ranking 29th among 31 sub-industries [6][18] - The report emphasizes the importance of high-end medical device innovation, supported by recent regulatory measures aimed at optimizing lifecycle management [13][14] Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 7552.12, with a 52-week high of 8490.25 and a low of 6070.89 [1] Recent Developments - Johnson & Johnson announced significant progress in PFA research at the HRS2025 conference, showcasing three key PFA products with excellent safety and efficacy profiles [4][5] - The report notes that six domestic brands have received approval for PFA technology, marking a significant step towards commercialization [5] Subsector Performance - All sub-sectors within the pharmaceutical and biotechnology industry experienced declines this week, with the largest drop in the other biological products sector at 6.7% [6][23] - The report provides a detailed breakdown of weekly performance across various sub-sectors, indicating a general trend of retraction [6][24] Recommended and Beneficiary Stocks - Recommended stocks include innovative pharmaceutical companies such as Xinda Biopharma and Kangfang Biopharma, as well as medical device firms like Yingke Medical and Maipu Medical [7][29] - Beneficiary stocks in the innovative drug sector include Zai Lab, Yifan Biopharma, and others, while the medical device sector includes companies like Mindray Medical and Aohua Endoscopy [7][29] Regulatory Insights - The report discusses the approval of measures to support high-end medical device innovation, which includes optimizing special approval processes and enhancing communication mechanisms [13][14] - The report suggests that the implementation of these measures will significantly benefit high-tech medical devices, including AI-assisted diagnostic tools [14][28]

Core Viewpoint - The transaction between the listed company and the target company aims to enhance business synergy and improve asset quality by integrating their operations in the biopharmaceutical sector, particularly focusing on cell culture products and CDMO services [1][2][3]. Group 1: Transaction Necessity and Business Integration - The listed company and the target company both operate in the biopharmaceutical sector, with the listed company focusing on cell culture products and CDMO services, while the target company specializes in CRO services for early-stage drug development [1][3]. - The transaction is seen as a strategic move to create synergies in business operations, customer bases, and international market strategies, enhancing the overall service offerings [2][4]. - The integration will allow the listed company to provide a comprehensive service chain from early drug development to commercial production, thereby improving customer retention and satisfaction [5][6]. Group 2: Financial Impact and Asset Quality Improvement - The transaction is expected to significantly improve the financial metrics of the listed company, with projected increases in total assets by 76.07% and net profit by 222.72% post-transaction [14][16]. - The integration will enhance the company's ability to withstand market fluctuations by diversifying its revenue streams, as CRO services are less correlated with the commercial production cycles of biopharmaceuticals [17][18]. - The merger will also reduce reliance on single product lines, allowing the company to offer a full range of services from early research to commercial production, thus strengthening its competitive position [17][19]. Group 3: Industry Trends and Strategic Alignment - The transaction aligns with industry trends where biopharmaceutical companies are increasingly seeking comprehensive service providers to streamline their drug development processes [19][20]. - The merger is consistent with industry practices where companies expand their capabilities through acquisitions to enhance service offerings and market competitiveness [19][20]. - The combined entity will be better positioned to compete with leading firms in the sector by offering integrated solutions that cover the entire drug development lifecycle [19][20]. Group 4: Integration Plans and Management Control - Post-transaction, the listed company plans to implement a comprehensive integration strategy that includes shared customer resources, joint marketing efforts, and unified management structures to enhance operational efficiency [22][23]. - The management team from the target company will remain in place, ensuring continuity while also integrating into the listed company's governance structure to facilitate effective oversight and control [26][30]. - The integration will focus on leveraging the strengths of both companies to create a robust platform for biopharmaceutical services, enhancing overall market presence and operational capabilities [22][23].

证券代码：300759 证券简称：康龙化成 公告编号：2025-031 康龙化成（北京）新药技术股份有限公司 2024年年度股东大会、2025年第一次A股类别股东大会及 2025年第一次H股类别股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1．本次股东大会是否出现否决提案的情形：否。 2．本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1．康龙化成（北京）新药技术股份有限公司（以下简称"公司"）2024 年年 度股东大会、2025 年第一次 A 股类别股东大会及 2025 年第一次 H 股类别股东 大会（以下简称"本次股东大会"）通知公告已于 2025 年 5 月 30 日以公告形式 发出。 2．会议召开的时间： （1）现场会议召开时间：2025 年 6 月 20 日（星期五）13:30； （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 6 月 20 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00；通 过深圳证券交易所互联网 ...

关于康龙化成（北京）新药技术股份有限公司 2024 年年度股东大会、2025 年第一次 A 股类别股东大会及 2025 年第一次 H 股类别股东大会的 北京市中伦律师事务所 法律意见书 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》及中国证券监督管理委员会发布的《上市公司股东会规则》等规 定，北京市中伦律师事务所（以下简称"本所"）接受康龙化成（北京）新药技 术股份有限公司（以下简称"公司"）的委托，指派本所律师对公司 2024 年年 度股东大会、2025 年第一次 A 股类别股东大会及 2025 年第一次 H 股类别股东 大会（以下简称"本次股东大会"）进行见证并就相关事项出具本法律意见书。 本法律意见书仅就本次股东大会的召集人资格、召集和召开程序、出席本次 股东大会人员的资格、会议表决程序是否符合法律、法规、规范性文件及《公司 章程》的规定以及表决结果是否合法有效发表意见，而不对本次股东大会所审议 的议案内容以及该等议案所表述的相关事实或数据的真实性、准确性或合法性发 表意见。 本法律意见书仅供公司本次股东大会之目的使用，未经本所书面同意不得用 作其他任何目的。 1 法 ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-032 鉴于康龙化成（北京）新药技术股份有限公司（以下简称"公司"）非执行 董事胡柏风先生因本职工作调整，申请辞去公司第三届董事会非执行董事及董事 会战略委员会委员职务，辞职后胡柏风先生将不再担任公司任何职务。公司于 2025 年 6 月 20 日召开 2024 年年度股东大会、2025 年第一次 A 股类别股东大会 及 2025 年第一次 H 股类别股东大会，审议通过了《关于补选公司第三届董事会 非执行董事的议案》，万璇女士当选为公司第三届董事会非执行董事。补选完成 后董事会及各专门委员会的人员组成情况如下： 一、公司第三届董事会组成情况 执行董事：Boliang Lou 先生（董事长）、楼小强先生、郑北女士 非执行董事：万璇女士、李家庆先生 独立非执行董事：曾坤鸿（Benson Kwan Hung Tsang）先生、余坚先生、李 丽华女士 二、公司第三届董事会各专门委员会组成情况 根据《公司法》《公司章程》及其他有关法律法规的规定，公司董事会设立 战略委员会、审计委员会、提名委员会、薪酬与考核委员会四个专门委员会，第 三届董事会各专门委员会委 ...

康龙化成（北京）新药技术股份有限公司 章程 （经公司于 2025 年 6 月 20 日召开的 2024 年年度股东大会、 2025 年第一次 A 股类别股东大会及 2025 年第一次 H 股类别股东大会审议通过） 中国 北京 | 第一章 | 总则 1 | | --- | --- | | 第二章 | 经营宗旨和经营范围 2 | | 第三章 | 股份 3 | | 第一节 | 股份发行 3 | | 第二节 | 股份增减和回购 6 | | 第三节 | 股份转让 8 | | 第四章 | 股东和股东大会 10 | | 第一节 | 股东 10 | | 第二节 | 股东大会的一般规定 14 | | 第三节 | 股东大会的召集 21 | | 第四节 | 股东大会的提案与通知 23 | | 第五节 | 股东大会的召开 26 | | 第六节 | 股东大会的表决和决议 31 | | 第七节 | 类别股东表决的特别程序 38 | | 第五章 | 董事会 40 | | 第一节 | 董事 40 | | 第二节 | 董事会 44 | | 第三节 | 独立非执行董事 51 | | 第四节 | 董事会秘书 56 | | 第六章 | 经理及其他高 ...

康龙化成（北京）新药技术股份有限公司 关于股东解除一致行动关系的公告 证券代码：300759 证券简称：康龙化成 公告编号：2025-033 本公司股东厦门龙泰鼎盛企业管理合伙企业（有限合伙）、厦门龙泰汇盛企业 管理合伙企业（有限合伙）、厦门龙泰汇信企业管理合伙企业（有限合伙）、厦门龙 泰众盛企业管理合伙企业（有限合伙）保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、本次解除一致行动关系是因公司股东的普通合伙人暨执行事务合伙人发 生变更所致，不涉及股东持股数量变动； 2、本次一致行动关系解除不会导致公司实际控制人发生变化。 一、基本情况 郑北女士是公司实际控制人之一、董事、执行副总裁，在公司首次公开发行 股票并上市时，其作为员工持股平台的普通合伙人暨执行事务合伙人，实际控制 员工持股平台所持有公司股份的表决权，员工持股平台为郑北女士的一致行动人。 在一致行动关系存续期间，各方在公司重大事项的决策上始终保持一致意见，严 格履行相关承诺事项，不存在滥用自身控制地位的情形。 2025 年 6 月 ...

Core Insights - Alibaba has re-emerged as a Limited Partner (LP) in the investment landscape, marking a significant shift after a period of reduced activity among internet giants [2][4] - The establishment of a new fund, "无限启航海河（天津）创业投资合伙企业," with an investment of approximately 140 million RMB, indicates Alibaba's renewed commitment to venture capital [2][4] - This move is seen as part of Alibaba's strategic adjustment, focusing on core business areas after divesting non-core assets and raising over 20 billion RMB [4] Investment Landscape - The overall LP investment in private equity funds in China has seen a decline, with a total subscription scale of approximately 1.48 trillion RMB in 2024, down 19.57% year-on-year [5][6] - Despite the challenges in fundraising, there is a resurgence of interest from industry LPs, with many looking to invest in emerging technologies such as AI and renewable energy [6][7] - Recent data shows that industry LPs are increasingly returning to the market, with significant participation from companies like Ningde Times and Kanglong Chemical [6][7] Market Sentiment - The sentiment in the venture capital market is improving, with industry leaders expressing optimism about 2025 being a new starting point for investment in future industries [7][8] - The return of major LPs like Alibaba is viewed as a positive signal for the venture capital ecosystem, potentially leading to increased investment activity [8]

Group 1 - The core viewpoint of the news is that the China Europe Medical Innovation Stock A (006228) has experienced a decline of 2.62% on June 19, with a cumulative drop of 9.02% over the last five trading days, indicating a downward trend in its performance [1] - As of the end of 2024, the fund has a total size of 4.675 billion yuan and has achieved a cumulative return of 33.78% since its establishment in February 2019 [1] - The holder structure shows that institutional investors hold 0.23 million shares, accounting for 0.61% of the total shares, while individual investors hold 38.37 million shares, making up 99.39% of the total [1] Group 2 - The current fund manager, Ms. Ge Lan, has a Ph.D. in Biomedical Engineering from Northwestern University and has extensive experience in the investment management field, having joined China Europe Fund Management in October 2014 [2] - Ms. Ge has managed several funds, including the China Europe Medical Health Mixed Securities Investment Fund since September 29, 2016, and has held various managerial positions in other funds [2] Group 3 - As of March 31, 2025, the top ten holdings of China Europe Medical Innovation Stock A account for a total of 75.62%, with the largest positions being WuXi AppTec (10.35%), Kelun-Biotech (10.15%), WuXi Biologics (9.82%), and WuXi AppTec (9.60%) [3]

6月19日，银华医疗健康量化优选A（005237）下跌1.40%，最新净值1.15元，连续5个交易日下跌，区 间累计跌幅7.42%。 截止2025年3月31日，银华医疗健康量化优选A前十持仓占比合计37.91%，分别为：恒瑞医药 （8.34%）、药明康德（6.43%）、百济神州-U（3.65%）、海思科（3.62%）、爱尔眼科（3.12%）、华 东医药（3.07%）、迈瑞医疗（2.92%）、科伦药业（2.70%）、东阿阿胶（2.12%）、康龙化成 （1.94%）。 来源：金融界 据了解，银华医疗健康量化优选A成立于2017年11月，基金规模0.22亿元，成立来累计收益率15.04%。 从持有人结构来看，截至2024年末，银华医疗健康量化优选A的基金机构持有0.10亿份，占总份额的 50.69%，个人投资者持有0.10亿份，占总份额的49.31%。 公开信息显示，现任基金经理马君女士:硕士学位。2008年7月至2009年3月任职大成基金管理有限公司 助理金融工程师。2009年3月加盟银华基金管理有限公司,曾担任研究员及基金经理助理职务。自2012年 9月4日至2020年11月30日担任银华中证内地资源主题指数分 ...